阿巴洛肽与阿仑膦酸钠对绝经后骨质疏松骨折风险的影响比较
该事后分析基于ACTIVE和ACTIVExtend研究,比较阿巴洛肽与阿仑膦酸钠的抗骨折疗效。
要点
- 阿巴洛肽初始治疗椎体骨折率显著低于阿仑膦酸钠。
- 非椎体骨折和临床骨折风险两组无显著差异。
- 序贯治疗中椎体骨折率在两组均进一步下降。
核心结论
- 在绝经后骨质疏松女性中,阿巴洛肽初始治疗可能比阿仑膦酸钠更有效降低椎体骨折风险。
研究设计与样本
- 事后分析,基于ACTIVE和ACTIVExtend研究,纳入ACTIVExtend中1139名女性,比较ACTIVE中安慰剂或阿巴洛肽治疗与ACTIVExtend中阿仑膦酸钠治疗的骨折率。
主要发现
- 从安慰剂换用阿仑膦酸钠后椎体骨折率从2.49降至1.66例/100患者年,从阿巴洛肽换用阿仑膦酸钠后从0.47降至0.19例/100患者年,但比较未达统计学显著性。
- 非椎体骨折和临床骨折率在阿巴洛肽与阿仑膦酸钠之间无显著差异。
临床怎么用
- 对于绝经后骨质疏松女性,可考虑阿巴洛肽初始治疗以更有效降低椎体骨折风险。
局限性
- 为事后分析,非头对头随机对照比较,结论需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The ACTIVE study demonstrated the antifracture efficacy of abaloparatide in postmenopausal women with osteoporosis. ACTIVExtend demonstrated sustained fracture risk reduction with alendronate in abaloparatide-treated participants from ACTIVE. A direct comparison of the efficacy of abaloparatide and antiresorptive therapies has not been performed. OBJECTIVE: The objective of this analysis is to compare the antifracture efficacy of abaloparatide in ACTIVE with that of alendronate in ACTIVExtend. DESIGN: In this post hoc analysis, the rate of new vertebral fractures for women in ACTIVExtend (N = 1139) was calculated based on baseline and endpoint radiographs for placebo or abaloparatide in ACTIVE and alendronate in ACTIVExtend. Vertebral fracture rates between abaloparatide and alendronate were compared in a Poisson regression model. Fracture rates for nonvertebral and clinical fractures were compared based on a Poisson model during 18 months of abaloparatide or placebo treatment in ACTIVE and 18 months of alendronate treatment in ACTIVExtend. RESULTS: The vertebral fracture rate was lower during abaloparatide treatment in ACTIVE (0.47 fractures/100 patient-years) than alendronate treatment in ACTIVExtend (1.66 fractures/100 patient-years) (relative risk reduction 71%; P = .027). Although the comparisons did not meet statistical significance, after switching from placebo (ACTIVE) to alendronate (ACTIVExtend), the rate of new vertebral fractures decreased from 2.49 to 1.66 fractures per 100 patient-years, and after switching from abaloparatide to alendronate from 0.47 to 0.19 fractures per 100 patient-years. The rates of nonvertebral fractures and clinical fractures were not significantly different. CONCLUSION: Initial treatment with abaloparatide may result in greater vertebral fracture reduction compared with alendronate in postmenopausal women with osteoporosis.
引用
- Leder BZ, Mitlak B, Hu MY, et al. Effect of Abaloparatide vs Alendronate on Fracture Risk Reduction in Postmenopausal Women With Osteoporosis. J Clin Endocrinol Metab. 2020. PMID: 31674644. doi:10.1210/clinem/dgz162
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。